Abstract
The α7-nAChR plays critical roles in numerous organs and cells by regulating highly organ and cell typespecific functions. In this special issue different Authors have contributed to clarify the different roles played by the α7- nAChR. Post-translational processes such as receptor “underactivation” or “overactivation” are associated in the central nervous system with brain disorders including neurodegeneration, while also contributing to the regulation of nonneuronal cells and cancers derived from them. Current advances in the knowledge of α7-nAChR biology encourage the exploitation of this receptor as a therapeutic target for a variety of diseases, including Alzheimer’s, disease, Parkinson’s disease, cognitive decline, pain and cancer.
Keywords: α7-nAChR, biological activity, future perspectives, new drugs, toxins
Current Drug Targets
Title:A New “Era” for the α7-nAChR
Volume: 13 Issue: 5
Author(s): Patrizia Russo, Alessio Cardinale, Hildegard Shuller
Affiliation:
Keywords: α7-nAChR, biological activity, future perspectives, new drugs, toxins
Abstract: The α7-nAChR plays critical roles in numerous organs and cells by regulating highly organ and cell typespecific functions. In this special issue different Authors have contributed to clarify the different roles played by the α7- nAChR. Post-translational processes such as receptor “underactivation” or “overactivation” are associated in the central nervous system with brain disorders including neurodegeneration, while also contributing to the regulation of nonneuronal cells and cancers derived from them. Current advances in the knowledge of α7-nAChR biology encourage the exploitation of this receptor as a therapeutic target for a variety of diseases, including Alzheimer’s, disease, Parkinson’s disease, cognitive decline, pain and cancer.
Export Options
About this article
Cite this article as:
Patrizia Russo, Alessio Cardinale, Hildegard Shuller , A New “Era” for the α7-nAChR , Current Drug Targets 2012; 13 (5) . https://dx.doi.org/10.2174/138945012800398946
DOI https://dx.doi.org/10.2174/138945012800398946 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tamoxifen and its New Derivatives in Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Macromolecular Drug Targets in Cancer Treatment and Thiosemicarbazides as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry The Potential and Rationale for COX-2 Inhibitors in Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies
Current Drug Targets Insights into Targeting Colon Cancer Cell Fate at the Level of Proteoglycans / Glycosaminoglycans
Current Medicinal Chemistry A Review of Pharmacological Treatment Options for Lung Cancer: Emphasis on Novel Nanotherapeutics and Associated Toxicity
Current Drug Targets Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy
Current Cancer Drug Targets Structural and Bioactive Properties of 3-O-Methylfunicone
Mini-Reviews in Medicinal Chemistry Proton Ion-Microbeam Elemental Analysis for Inhaled Particle-Induced Pulmonary Diseases: Application for Diagnosis and Assessment of Progression
Current Medicinal Chemistry Death Receptor Ligands: New Strategies for Combined Treatment with Ionizing Radiation
Current Medicinal Chemistry - Anti-Cancer Agents Angiogenesis Inhibition: State of the Art, Forgotten Strategies and New Perspectives in Cancer Therapy
Current Cancer Therapy Reviews Updated Review and Perspective on 20S Proteasome Inhibitors in the Treatment of Lung Cancer
Current Cancer Drug Targets Current Molecularly Targeting Therapies in NSCLC and Melanoma
Anti-Cancer Agents in Medicinal Chemistry Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry PDGF-D Signaling: A Novel Target in Cancer Therapy
Current Drug Targets Hypericin Lights Up the Way for the Potential Treatment of Nasopharyngeal Cancer by Photodynamic Therapy
Current Clinical Pharmacology Targeting the Hippo Pathway for Anti-cancer Therapies
Current Medicinal Chemistry PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Overview on Anticancer Drug Design and Development
Current Medicinal Chemistry Malignant Mesothelioma: Biology, Diagnosis and Therapeutic Approaches
Current Molecular Pharmacology